In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

The FDA approval comes on the back of the BLISS-LN trial results, which showed that 43% of patients on Benlysta hit the target of a significant improvement in kidney function, compared with 32% of ...